linjc16/ctgov huggingface dataset:
Granulomatous Pneumocystis Pneumonia

Study Overview
=================
Brief Summary
-----------------
The intra-alveolar form of Pneumocystis jiroveci pneumonia (PjP) is a common pathology in immunocompromised patients, particularly those infected with HIV. The diagnosis is based on the detection of Pj in a LBA. Intra-tissue granulomatous form (PGP) is a rare entity observed in non-HIV immunocompromised patients. In this case, the LBA is mostly non-contributory and the diagnosis is based solely on the detection of cysts on histological examination on biopsy of a pulmonary nodule. For many years, it has been clearly demonstrated that the use of a specific PCR clearly improves the biological diagnosis of PcP. However, in case of granulomatous form this method is not implemented because the diagnostic hypothesis is not mentioned. In 2018, two cases of PGP were diagnosed at 3-month intervals at Montpellier University Hospital Center. The diagnostic confirmation was obtained with PCR Pj. In this context the investigators will investigate the interest of implementing PCR Pj on biopsies on pulmonary nodules from hospitalized patients between 2015 and 2018. In all selected patients, histopathological aspect of the nodule was compatible with a PGP and, no other diagnosis has been confirmed (infectious, tumoral, inflammatory ...). Finally, 17 patients were selected to check retrospectively, if the presence of Pj could be at the origin of the pathology.

Official Title
-----------------
Biological Diagnosis of Granulomatous Pneumocystis Pneumonia

Conditions
-----------------
Pulmonary Nodule, Invasive Fungal Infections, Pneumocystis Jirovecii

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pulmonary nodule Exclusion Criteria: nodule : tumoral, other infections than Pj, inflammatory

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PCR results | PCR results | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Granulomatous Pneumocystis Pneumonia, PCR Pneumocystis jirovecii
Sedation Protocols and Skeletal Muscle Metabolism in Mechanical Ventilated Patients

Study Overview
=================
Brief Summary
-----------------
To investigate the effects of different sedation protocols on skeletal muscle metabolism in mechanical ventilated patients in ICU. Mechanical ventilated patients who are anticipated to stay in ICU for more than 5 days are enrolled and randomly assigned to the following three groups, interventional group(dexmedetomidine), control group(midazolam) and no sedation group. Serum, CT scan of intercostal muscles, ultrasound evaluation of quadriceps femoris are obtained.

Official Title
-----------------
The Effect of Different Sedation Protocols on Skeletal Muscle Metabolism in Mechanical Ventilated Patients

Conditions
-----------------
Hypercatabolism, Sedative, Hypnotic, or Anxiolytic Use Disorders

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine
* Drug: Midazolam


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mechanical ventilated for more than 48h 18-80 years stay in ICU for more than 5 days Exclusion Criteria already participated in other clinical trials pregnancy or lactation lower limb amputation primary neuro-muscular disease disseminated tumor or accepted special therapy alcohol abuse severe liver dysfunction(Child-Push C) unstable angina/acute myocardial infarction heart rates<50bpm all kinds dialysis severe burn epidural anesthesia severe neurological disease（acute stroke, uncontrollable epilepsy, severe dementia, etc）

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexmedetomidine group<br>Dexmedetomidine consistent infusion as sedative. | Drug: Dexmedetomidine<br>* consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.<br>|
| Active Comparator: Midazolam group<br>Midazolam consistent infusion as sedative. | Drug: Midazolam<br>* consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acute muscle wasting | measured by 3-MH release in serum | From date of randomization to extubation,up to 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day mortality | death rate within 28 days after mechanical ventilation | From date of randomization to date of death from any cause,up to 28 days | 
| length of ICU stay | time from enrollment to discharge or die | From date of randomization to date of to discharge or death,up to 28 days |
The Impact of Nurses' Emotional Labor on Job Satisfaction and Burnout

Study Overview
=================
Brief Summary
-----------------
Emotional labor is one of the bases that organizations earn profits. Nursing care needs high emotional labor to offer health care to patients. Among health carers that emphasize a lot on emotional labor, nurses are especially required to include emotional labor as very important parts of their jobs.

Detailed Description
-----------------
This study intends to investigate the association among emotional labor, job satisfaction, and burnout. Furthermore, the moderating effect of job stress , job involvement and emotional intelligence will be studied. The study population includes all nurses (N=18,446) of Taiwan's medical centers. Of which, 20% of randomly selected six medical centers will be delivered a questionnaire in order to further analyze the association of study variables. The level of emotional labor, burnout, job satisfaction, job stress, job involvement and emotional intelligence of the study samples collected from questionnaires will be analyzed by using descriptive statistics, variance analyses, and SEM techniques in order to understand more the associations among study variables. Results of this study are expected to work as references to improve job satisfaction and decrease the level of burnout of nurses.

Official Title
-----------------
The Impact of Nurses' Emotional Labor on Job Satisfaction and Burnout

Conditions
-----------------
Satisfaction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: licensed nurses in the hospitals Exclusion Criteria: part-time nurses nurses who work under a year in the hospitals

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emotional Labor, Burnout, Job Satisfaction, Emotional Intelligence, Job stress, Job involvement
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate the utility of 99mTc-sestamibi SPECT/CT imaging for the diagnosis of renal oncocytomas.

Official Title
-----------------
Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

Conditions
-----------------
Clinical T1 Renal Mass

Intervention / Treatment
-----------------
* Other: Preoperative 99mTc-Sestamibi SPECT/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presence of a solid enhancing cT1 renal mass detected on cross-sectional imaging Scheduled to undergo surgery with either partial or radical nephrectomy Age ≥18 years Exclusion Criteria: Pregnancy Evidence of nodal or distant metastases History of other malignancy with concern for renal metastasis Known allergy to technetium or sestamibi

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Preoperative 99mTc-Sestamibi SPECT/CT<br> | Other: Preoperative 99mTc-Sestamibi SPECT/CT<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of preoperative 99mTc-sestamibi SPECT/CT findings with tumor histology following surgical resection. |  | Within 2 weeks of surgery |
Efficacy and Tolerability CVI (A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial (CVI)

Study Overview
=================
Brief Summary
-----------------
To determine efficacy and tolerability of Antistax 360 mg tablets in chronic venous insufficiency linked to edema (swelling) and subjective symptoms

Official Title
-----------------
A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency.

Conditions
-----------------
Venous Insufficiency

Intervention / Treatment
-----------------
* Drug: Read vine leaf extract (AS 195)


Participation Criteria
=================

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Read vine leaf extract (AS 195)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in limb volume of the more affected leg on day 84 , determined by water displacement. |  | 84 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in limb volume on days 21 and 42 determined by water displacement. |  | 21 and 42 days | 
| Change from baseline in calf circumference on days 21, 42, and 84 |  | 21, 42 and 84 days | 
| Change from baseline in the subjective symptoms of CVI (tired heavy legs, sensation of tension in the legs, tingling sensations in the legs, pain in the legs) measured by visual analogue scales (VAS) on days 21, 42, and 84 |  | 21, 42 and 84 days | 
| Global assessment of efficacy by the patient on day 84 |  | 84 days | 
| Global assessment of efficacy by the investigator on day 84 |  | 84 days | 
| Change from baseline in quality of life as determined by the Tuebingen QoL Questionnaire on day 84 |  | 84 days | 
| Incidence of adverse events |  | 84 days | 
| Measurement of vital signs (pulse rate, blood pressure) |  | 84 days | 
| Global assessment of tolerability by the patient and by the investigator on day 84. |  | day 84 |
Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether T900607-sodium is effective and safe in treating non-Hodgkin's lymphoma.

Conditions
-----------------
Non-Hodgkin's Lymphoma

Intervention / Treatment
-----------------
* Drug: intravenous T900607-sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Histologically or cytologically confirmed diagnosis of non-Hodgkin's lymphoma (NHL) Subjects must have received prior chemotherapy for their NHL At least 18 years of age Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size. Karnofsky performance status of at least 70% Estimated life expectancy of at least 12 weeks Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive Subject must be able to comply with study procedures and follow-up examinations. Signed written informed consent Lab Values (obtained ≤ 7 days prior to study enrollment): ANC at least 1.5x10e9/L, Platelet count at least 100x10e9/L, Hemoglobin at least 8.5 g/dL, Creatinine within 2 times upper limit of normal, AST and ALT within 3 times upper limit of normal, Bilirubin within 1.5 times upper limit of normal, Albumin great than 2.5 g/dL, Exclusion Criteria Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms Patients who have received any investigational agent within 4 weeks of enrollment Patients who are pregnant or breast-feeding History of prior malignancy other than NHL within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix History of central nervous system metastases or carcinomatous meningitis Major surgery within 4 weeks of enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: intravenous T900607-sodium|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NHL
Profiling of Post Covid-19 Infection Patients: an Online Survey

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to explore the relation between indicators of central sensitisation, quality of life and functional status in patients post covid-19 infection.

Official Title
-----------------
Profiling of Post Covid-19 Infection Patients: an Online Survey

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: Filling in an online survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female adults who were previously infected with covid-19

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Persons who had a covid-19 infection.<br>Male and female adults who were previously infected with covid-19. | Other: Filling in an online survey<br>* Patients are asked to fill in an online survey regarding functional status, quality of life and symptoms of central sensitisation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional status | Post-COVID-19 functional status is evaluated by the Post-COVID-19 Functional Status Scale. | Up to 18 months after infection with Covid-19. | 
| Health-related Quality of life | The EuroQol with five dimensions and three levels is used to evaluate health-related quality of life. | Up to 18 months after infection with Covid-19. | 
| Symptoms of central sensitisation | Symptoms of central sensitisation are assessed by the Central Sensitization Inventory. | Up to 18 months after infection with Covid-19. |
The Incidence of Congenital Undescended Testis Among Dutch Infants

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the incidence of congenital undescended testis of mature boys, at one year of age, born in the Medical Centre Alkmaar (MCA).

Detailed Description
-----------------
The position of the testes of mature boys will be registered at birth and boys with a high-scrotal, non-scrotal or dubious position of the testis/ testes will be followed up (till the age of one year).

Official Title
-----------------
The Incidence of Congenital Undescended Testis Among Dutch Infants in the Medical Centre Alkmaar

Conditions
-----------------
Undescended Testis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mature newborns (>/= 37 weeks) born in the Medical Centre Alkmaar Exclusion Criteria: premature newborns (< 37 weeks)

Ages Eligible for Study
-----------------
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
congenital, high scrotal
The Treatment Advocacy Program

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to test the efficacy of TAP, a behavioral intervention, in improving sexual safety and treatment adherence among gay and bisexual men infected with HIV. It is hypothesized that those who are in the intervention group will report reductions in unprotected sex with HIV-negative and unknown-status partners; and will show stricter adherence to their treatment regimens, compared to the individuals in the standard-of-care, control group.

Official Title
-----------------
The Treatment Advocacy Program

Conditions
-----------------
HIV

Intervention / Treatment
-----------------
* Behavioral: TAP: Treatment Advocacy Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV+ men who have sex with other men, age 18 or over, in HIV care at one of the collaborating clinics, any sexual contact within the previous six months. Exclusion Criteria: self-reported low likelihood of remaining in treatment or in the study location for 12 months, inability to comprehend the consent quiz administered during the Consent and Enrollment Visit, or unwilling to provide required locator information

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: TAP: Treatment Advocacy Program|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported, unprotected (without condoms) anal or vaginal sex with HIV-negative or unknown-status partners. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-reported incidences of missed doses of treatment regimen. |  |  |
Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli

Study Overview
=================
Brief Summary
-----------------
Retrospective study of patients diagnosed with a nasopharyngeal carcinoma included in our data base care between June 1990 and September 2013. Our hypothesis is: Our series of patients with a history of nasopharyngeal carcinoma presents epidemiological, response rates to the different treatments and survival similar to those described in the literature

Detailed Description
-----------------
Retrospective study of 50 patients diagnosed with nasopharyngeal carcinoma. The following variables will be studied: age, sex, toxic habits , associated pathology, patient origin , first symptom , duration , histology, stage , second malignancies , recurrences , metastases , treatments performed , the response thereto and survival.

Official Title
-----------------
Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli

Conditions
-----------------
Nasopharyngeal Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed of Nasopharyngeal Carcinoma at Ear-Nose-Throat Department at Corporació Sanitària Parc Taulí from 1993 to 2013 Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nasopharyngeal Carcinoma<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of Nasopharyngeal Carcinoma Patients | Describe our population diagnosed nasopharyngeal carcinoma and compared in epidemiology and therapeutic results with those in the literature | 1 year after diagnostic | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasopharyngeal Carcinoma